Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab versus platinum-based chemotherapy as first-line treatment for PD-L1-high advanced NSCLC
NL-OMON46307Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Durvalumab monotherapy with Standard-of-care platinum-based chemotherapy (2 arms). Primary endpoint: Overall survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46307.